永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

提前休市 12-24 12:00:00

2.680

-0.070

-2.55%

最高2.780	最低2.670	成交量17.20万
今开2.780	昨收2.750	日振幅4.00%
总市值16.56亿	流通市值16.56亿	总股本6.18亿
成交额46.49万	换手率0.03%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.68,"timestamp":1766548800014,"preClose":2.75,"halted":0,"volume":171964,"delay":0,"floatShares":618000000,"shares":618000000,"eps":-0.4032252625091379,"marketStatus":"提前休市","change":-0.07,"latestTime":"12-24 12:00:00","open":2.78,"high":2.78,"low":2.67,"amount":464914,"amplitude":0.04,"askPrice":2.72,"askSize":6000,"bidPrice":2.67,"bidSize":7000,"shortable":0,"etf":0,"ttmEps":-0.48215652244412305,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":6,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.75,"openAndCloseTimeList":[[1766539800000,1766548800000]],"volumeRatio":0.206974,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2593422894","title":"优宁维：创新药研发是公司产品主要应用领域之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2593422894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593422894?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:05","pubTimestamp":1766559928,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：祁总，公司有没有向创新药或者脑机接口进军布局？优宁维回复：投资者您好，公司主要面向国内高等院校、科研院所、医院和生物医药企业等科研端，提供生命科学试剂、设备、耗材、综合技术服务等产品和服务。创新药研发是公司产品的主要应用领域之一。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","06978","BK0250","301166","159992"],"gpt_icon":0},{"id":"2593213634","title":"审批进度加快，年末多款创新药集中获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2593213634","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593213634?lang=zh_cn&edition=full","pubTime":"2025-12-24 13:56","pubTimestamp":1766555761,"startTime":"0","endTime":"0","summary":"江海证券研报认为，此次“四连发”不仅是审评审批效率的体现，更标志着中国创新药研发成果迎来一轮密集的上市收获期。2024年，我国有48个创新药获批上市。此前的12月7日，国家药监局党组成员、副局长杨胜对外表示，今年以来，中国批准上市的创新药，截至当天，达到69个，已经超过了去年全年，再次创造了历史新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224135811953b98c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224135811953b98c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","09969","LU2488822045.USD","BK1161","06978","BK1574","09688"],"gpt_icon":0},{"id":"2593419285","title":"普华永道徐佳：中国创新药迎分水岭，量质转型呈分化格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419285","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419285?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:54","pubTimestamp":1766494448,"startTime":"0","endTime":"0","summary":"普华永道中国医药医疗行业主管合伙人徐佳博士在接受21世纪经济报道记者专访时指出，中国创新药已进入“量质转型的分水岭阶段”，呈现“头部崛起、中小突围”的分化格局，而非行业全面复苏。当前，随着2025年国家医保药品目录正式披露，支付端对创新药的支持力度","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223205718a46f0791&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223205718a46f0791&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","HK0000165453.HKD","LU2328871848.SGD","LU2097828474.EUR","LU2097828557.USD","LU2097828805.USD","09969","01801","LU2242644610.SGD","LU2097828714.EUR","LU0502904849.HKD","LU1969619763.USD","LU2488822045.USD","BK1161","LU0455707207.USD","BK1589","01530","LU2097828631.EUR","06978","BK1583"],"gpt_icon":0},{"id":"2593498324","title":"十年深耕：中国创新药授权交易从“爆发”迈向“长红”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593498324","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593498324?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:24","pubTimestamp":1766478262,"startTime":"0","endTime":"0","summary":"BD（商务拓展），曾在生物医药领域融资市场持续收紧的“资本寒冬”中，为中国生物科技公司（Biotech）带来了新的募资契机。2025年，BD掀起了前所未有的热潮。央视财经数据显示，截至2025年11月18日，国产创新药对外授权总金额已突破千亿美元，相较于2024年实现了翻倍式增长。手握优质BD项目的Biotech迎来了股价上涨、IPO畅通等红利，更有不少企业提前预告BD进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233599517231.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599517231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","159992","06978","BK1574"],"gpt_icon":0},{"id":"2593245462","title":"聚焦肺癌围术期免疫治疗新发展，让高品质创新药惠及更多患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2593245462","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593245462?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:21","pubTimestamp":1766474482,"startTime":"0","endTime":"0","summary":"由北京中西医慢病防治促进会发起、百济神州支持的肺癌围术期全程管理规范化诊疗学术交流会日前举行。来自全国的肺癌专家齐聚一堂，共同讨论肺癌围术期免疫治疗最新研究成果及临床经验，推动肺癌免疫治疗的规范化、精准化发展，为患者提供更为科学、有效的治疗方案，最终提升我国肺癌治疗的整体水平与国际竞争力。肺癌是我国发病率与死亡率最高的恶性肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599448769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2593462595","title":"创新药板块的强心剂! 富国银行押注Arcellx(ACLX.US)重塑骨髓瘤治疗格局 预言股价将涨超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593462595","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593462595?lang=zh_cn&edition=full","pubTime":"2025-12-23 14:58","pubTimestamp":1766473090,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华尔街金融巨头富国银行对于美国生物科技新生代势力Arcellx启动评级与目标价覆盖并给予“增持”评级，称其用于多发性骨髓瘤的试验性CAR-T疗法“anito-cel”，是这种血液癌症管理系统中的“未来支柱”，未来将彻底重塑骨髓瘤治疗格局。今年以来Arcellx股价表现不佳，年内迄今跌超15%，大幅跑输标普500指数。在富国银行等知名卖方机构的分析师们看来，anito-cel有望彻底颠覆现有的多发性骨髓瘤治疗市场格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1267930490.SGD","LU0048573561.USD","LU0128525929.USD","BK4559","LU2236285917.USD","LU0477156953.USD","LU0648001328.SGD","LU0971096721.USD","LU0310800379.SGD","LU0128525689.USD","LU1506573853.SGD","LU0289960550.SGD","BK4207","LU0154236417.USD","LU0130517989.USD","LU1668664300.SGD","LU1267930227.SGD","LU0314106906.USD","IE000M9KFDE8.USD","LU1035773651.USD","LU1363072403.SGD","LU0149725797.USD","LU0211328371.USD","LU0640476718.USD","LU1069347547.HKD","LU0251142724.SGD","IE0002270589.USD","LU2361045086.USD","BK4139","IE00B7SZLL34.SGD","BK1574","LU0106831901.USD","06978","BK4504","159992","LU0787776722.HKD","ACLX","LU0683600562.USD","LU1074936037.SGD","LU0175139822.USD","LU0868494617.USD","LU2361044949.HKD","LU2461242641.AUD","LU0130102774.USD","LU1814569148.SGD","LU0868494708.USD","BK1161","LU0417517546.SGD","LU1791807156.HKD","LU0942090050.USD"],"gpt_icon":0},{"id":"2593045079","title":"信达生物“染蓝”：中国创新药从故事到资产的成人礼","url":"https://stock-news.laohu8.com/highlight/detail?id=2593045079","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593045079?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:33","pubTimestamp":1766457227,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛资本市场对于中国创新药的态度，在过去的几年间经历了剧烈的摇摆。在行业高歌猛进时，biotech往往被描绘为前景无限的未来之星；而当周期下行时，它们又被打上“高风险、不确定性”的标签。恒生指数的选择标准——市场规模、流动性及财务稳定性，直指投资逻辑的核心。这些传统的价值标尺与过往专注于“讲故事”的biotech企业估值体系形成了鲜明对比。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233599280151.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599280151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","LU2242644610.SGD","LU2097828805.USD","BK1161","LU1969619763.USD","159992","BK1589","LU2097828474.EUR","LU2097828557.USD","LU2328871848.SGD","LU2097828714.EUR","LU0502904849.HKD","BK1583","06978","01801","LU2488822045.USD","LU2097828631.EUR","LU0455707207.USD","HK0000165453.HKD"],"gpt_icon":0},{"id":"1130488131","title":"港股创新药概念股盘中拉升！石药集团涨超5%，荣昌生物涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130488131","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130488131?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:04","pubTimestamp":1766455472,"startTime":"0","endTime":"0","summary":"12月23日，港股创新药概念股盘中拉升，$石药集团(01093)$涨超5%，$恒瑞医药(01276)$、$三生制药(01530)$涨近3%，$先声药业(02096)$、$歌礼制药-B(01672)$、$康诺亚-B(02162)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26e483f2c2080ad5ab71efdf30a08f1a","theme_name":"🔥热榜No.24 · 石药集团获主席蔡东晨增持引发股价大幅上涨","theme_type":2,"isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","02162","02096","01477","01276","06978","01093","01672"],"gpt_icon":0},{"id":"2593936724","title":"2025年岁末，国产创新药出海热潮再起！涉及先声药业、荃信生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2593936724","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593936724?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:42","pubTimestamp":1766454156,"startTime":"0","endTime":"0","summary":"2025年进入12月，国产创新药出海热潮再次掀起。如12月22日，先声药业发布公告，与Ipsen签订了独家授权许可协议，涉及其开发的抗体药物偶联物SIM0613。此外，长春高新、复星医药等多家药企均在本月宣布达成创新药授权合作。从单个企业的零星出海，到产业层面的批量突围，2025年岁末的国产创新药出海热潮，标志着中国医药创新已站在新的历史起点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223094420a46c9ab2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223094420a46c9ab2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02509","02096","BK1574","BK1191","BK1161","06978","02142"],"gpt_icon":0},{"id":"2593148175","title":"沙利文毛化：中国创新药2026年迎升浪，加速国际化价值兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2593148175","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593148175?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:16","pubTimestamp":1766402190,"startTime":"0","endTime":"0","summary":"近一年来，中国药企在国际舞台上频频亮相，国际社会对中国制药业的发展关注度持续攀升。正如《经济学人》所指出的：中国创新药正处于全球化的临界点。从中国临床试验的参与度到对外授权许可的规模，中国药企在全球市场的占比均显著提升；过去一年，中国生物科技企业的股价涨幅远超美国同类企业，这一切无不表明，全球生物医药创新长达一个世纪的“西方主导”格局正悄然改变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512223598433738.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598433738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2593485369","title":"海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485369","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485369?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:36","pubTimestamp":1766396197,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司子公司辽宁海思科制药有限公司于近日收到国家药品监督管理局下发的《受理通书》，涉及药品：“HSK46575”。本次获得受理的为本品联合奥拉帕利片或联合多西他赛和泼尼松片用于前列腺癌的治疗适应症的临床试验申请。HSK46575片是公司自主研发的一种口服、强效和高选择性的小分子抑制剂，拟用于前列腺癌的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK0028","BK0077","BK1574","BK0033","002653","159992","BK0188","06978","BK0239","BK1161"],"gpt_icon":0},{"id":"2593043083","title":"罕见病治疗药物贝捷迈在华获批 国内首个获批用于TGCT治疗一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2593043083","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593043083?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:28","pubTimestamp":1766395680,"startTime":"0","endTime":"0","summary":"贝捷迈是一款由和誉医药研发的集落刺激因子-1受体抑制剂，也是国内首个获批用于TGCT治疗的一类创新药。“随着贝捷迈在全球的首个注册获批，我们正持续践行改善罕见肿瘤患者生活的承诺。”蔻德罕见病中心创始人、主任，瑞鸥公益基金会创始人、秘书长黄如方表示，随着贝捷迈在中国获批，这一类系统性治疗方案能够有效控制肿瘤进展、缓解症状，也让患者看到了希望。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222173226a469d45d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222173226a469d45d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BPRC5H50.USD","BK1161","02256","LU2476274308.USD","06978","LU2488822045.USD","IE00B543WZ88.USD","BK1574","LU2476274720.SGD","IE00B5MMRT66.SGD","LU2778985437.USD"],"gpt_icon":0},{"id":"2593102524","title":"高特佳于建林：锚定下一代疗法，创新药行业走向价值深化","url":"https://stock-news.laohu8.com/highlight/detail?id=2593102524","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593102524?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:43","pubTimestamp":1766389389,"startTime":"0","endTime":"0","summary":"随着我国生物医药产业竞争力与创新活力持续攀升，2025创新药高质量发展大会上国家医保局披露最新数据显示，年内中国批准上市的创新药已达69个，超过去年全年的48个，再次创下历史新高。当前，中国医药产业规模已位居全球第二，创新药在研数目约占全球的30%。这一高质量发展态势的背后，离不开政策的持续赋能，也得益于我国创新药企的深耕加码。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512223598279916.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598279916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159992","06978","BK1161"],"gpt_icon":0},{"id":"2593010404","title":"【IPO追踪】创新药概念遭遇罕见挫败，华芢生物上市即破发","url":"https://stock-news.laohu8.com/highlight/detail?id=2593010404","media":"IPO解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593010404?lang=zh_cn&edition=full","pubTime":"2025-12-22 14:49","pubTimestamp":1766386150,"startTime":"0","endTime":"0","summary":"总的来看，华生物在香港公开发售方面的表现不错，认购倍数较高。根据资料，华生物是一家总部位于中国的生物制药公司，致力于开发各类疗法，重点是针对有医疗需求及市场机会的适应症开发蛋白质药物。此外，华生物还有八款其他候选产品。希迪智驾跌14%，一手蚀387港元岁末新股热潮，六股同日招股！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222152356a6c04bb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222152356a6c04bb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02396","06978"],"gpt_icon":1},{"id":"2593530101","title":"三连涨后首度回调，港股通创新药ETF（520880）跌近1%高频溢价！机构：关注“硬创新”+“强出海”创新药资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2593530101","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593530101?lang=zh_cn&edition=full","pubTime":"2025-12-22 14:45","pubTimestamp":1766385900,"startTime":"0","endTime":"0","summary":"12月22日，港股通创新药板块三连涨后首度回调，高人气港股通创新药ETF午后一度跌近1%，场内再现高频溢价，显示买盘资金较为活跃。未来，应关注部分优质创新药资产，一是“硬创新”资产，二是具备较强出海潜力的资产。　　把握创新药低吸窗口期，首选同类最大港股通创新药ETF及其场外联接基金，标的指数恒生港股通创新药精选指数具备三大独特优势：","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-22/doc-inhcsexm7825049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1574","BK1161","520880"],"gpt_icon":0},{"id":"2593101186","title":"千亿美元交易引爆全球：2025年中国创新药出海的飞跃时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2593101186","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593101186?lang=zh_cn&edition=full","pubTime":"2025-12-22 14:43","pubTimestamp":1766385783,"startTime":"0","endTime":"0","summary":"2025年，中国创新药产业站在了全球医药创新版图的重要位置。这一年，对外授权（BD）交易总额历史性突破1000亿美元，百亿美元级超级订单密集落地；合作模式从“卖青苗”式的一次性出售，升级为“成本共担、利益共享”的尝试；研发管线结构显著优化——非肿瘤研发管线占比逼近肿瘤管线，自免、代谢、中枢神经、纤维化、抗感染等新兴赛道成为增长主力；资本市场同步强势反弹，政策支持体系持续完善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512223598230937.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598230937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","BK1574","BK1161"],"gpt_icon":0},{"id":"2593888434","title":"以商业化验证价值，以平台整合资源：云顶新耀重塑创新药商业逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2593888434","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593888434?lang=zh_cn&edition=full","pubTime":"2025-12-22 07:28","pubTimestamp":1766359680,"startTime":"0","endTime":"0","summary":"正因拥有商业化“确定性引擎”的带动，云顶新耀的自主研发“成长性引擎”才会被市场寄予厚望。这一布局背后，深刻凸显了云顶新耀在商业化平台能力建设上的长远战略考量。最终，通过这一梯队化布局，云顶新耀将构建起具备长期竞争壁垒的生态护城河。当前，国内创新药行业正面临“产品同质化严重、商业化转化能","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222081630a6bed6d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222081630a6bed6d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01952","BK1161","BK1583","06978"],"gpt_icon":0},{"id":"2593276791","title":"瑞博生物通过聆讯：强大技术壁垒叠加专而精管线，港市再迎稀缺创新药标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2593276791","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593276791?lang=zh_cn&edition=full","pubTime":"2025-12-21 22:25","pubTimestamp":1766327159,"startTime":"0","endTime":"0","summary":"随着中国小核酸药物主要开拓者——瑞博生物通过港交所聆讯，港股市场又增添了一家极具稀缺价值的创新药标的。故此，国内如瑞博生物这样能够突破行业技术壁垒并接近商业化前夕的创新药企可谓凤毛麟角。据悉，瑞博生物是全球为数不多拥有自主研发且经过临床验证的GalNAc递送技术的企业之一，该技术基于对siRNA药物特异性递送，增强了疗效和改善了安全性，正在颠覆创新药物的治疗理念。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06978","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2592955166","title":"创新药、新能源车等全线拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2592955166","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592955166?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:51","pubTimestamp":1766141516,"startTime":"0","endTime":"0","summary":"【导读】港股三大指数集体收涨12月19日，港股三大指数高开高走，截至收盘，恒生指数上涨0.75%，恒生科技指数上涨1.12%，恒生国企指数上涨0.68%。创新药、新能源汽车等涨幅靠前具体来看，当日权重科技股集体上涨，腾讯、快手、网易、美团、百度均涨超1%。板块方面，当日创新药概念股涨幅靠前，其中，映恩生物涨幅达9.29%，药明生物涨幅达4.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512193596898585.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596898585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["161028","06978","BK1161","BK1574","159992","399417"],"gpt_icon":0},{"id":"2592417196","title":"医保引路，企业破局——从科伦博泰看创新药的“中国路径”","url":"https://stock-news.laohu8.com/highlight/detail?id=2592417196","media":"中国财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592417196?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:24","pubTimestamp":1766139849,"startTime":"0","endTime":"0","summary":"日前，2025年国家医保药品目录调整工作圆满收官。科伦博泰总经理葛均友表示。“今年纳入医保的创新药共同特征是：填补临床空白、同类最优、更具性价比。”医保谈判桌前的一来一往，实质上是国家医疗需求与企业创新方向的对齐过程。在这条道路上，每一次双向奔赴，都在让“健康中国”的愿景更加清晰可见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219182632a45fad9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219182632a45fad9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990","BK1574","06978","LU0196878994.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0283},{"period":"1month","weight":-0.1297},{"period":"3month","weight":-0.4022},{"period":"6month","weight":-0.0833},{"period":"1year","weight":0.1458},{"period":"ytd","weight":0.1957}],"compareEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":0.022},{"period":"3month","weight":-0.0281},{"period":"6month","weight":0.0596},{"period":"1year","weight":0.2963},{"period":"ytd","weight":0.2849}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括EAL和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.057768}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}